Physician profile
Michael D Mitchell
NPI 1306001664
$2,886.71
in general payments reported to CMS, 2019-2025
19 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $548 · 2021: $416 · 2022: $356 · 2023: $80.42 · 2024: $460 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698 · Travel and Lodging: $9.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.57 |
| Travel and Lodging | $9.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,188.60 | 2019-2024 | Xarelto |
| Pfizer INC. | $599.67 | 2019-2023 | |
| Abiomed | $278.13 | 2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $176.46 | 2019-2022 | |
| Abbott Laboratories | $106.48 | 2025 | Jot Dx |
| Novartis Pharmaceuticals Corporation | $86.54 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $76.30 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $57.65 | 2022 | |
| Silk Road Medical, INC. | $48.02 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Abbvie INC. | $37.46 | 2021-2025 | |
| Astellas Pharma US INC | $35.82 | 2019-2020 | |
| Amgen INC. | $35.29 | 2020-2022 | |
| Alcresta Therapeutics, INC. | $29.29 | 2023-2024 | Relizorb |
| Astrazeneca Pharmaceuticals LP | $25.05 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.21 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $22.90 | 2023 | Tandemlife |
| Gilead Sciences, INC. | $22.56 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.52 | 2024 | Lifevest |
| Dexcom, INC. | $15.76 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.